Metabolic Effects of Newer Antipsychotics in Older Patients
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
San Diego |
| State: |
|
California |
| Zip Code: |
|
92037 |
| Conditions: |
|
Schizophrenia - Alzheimer's Disease - Dementia |
| Purpose: |
|
This study will compare four atypical antipsychotic medications in terms of the risk of
specific side effects each of them presents in middle-aged and elderly individuals.
|
| Study Summary: |
|
Atypical antipsychotic medications introduced within the last decade have been used
increasingly for the treatment of several types of psychotic disorders and severe behavioral
disturbances in older individuals. This trend is primarily due to a decrease in side effects
caused by the new medications, as compared to conventional neuroleptic medications. There is
a lower risk for developing tardive dyskinesia and extrapyramidal symptoms, both of which
are movement abnormalities, with new antipsychotic medications. However, there has been a
growing concern that the newer medications can cause a different set of potentially serious
adverse side effects. Specifically, they may cause long-term metabolic, cardiovascular, and
cerebrovascular effects, which may result in weight gain, diabetes, or stroke. This study
will compare four atypical antipsychotic medications in terms of the risk of metabolic,
cardiovascular, and cerebrovascular side effects that each presents in middle-aged and
elderly individuals.
Participants in this open-label study will be randomly assigned to receive one of three
atypical antipsychotic medications: aripiprazole; olanzapine; or risperidone. Although
assignment is random, a technique that may reflect the participant's own interests or the
researcher's knowledge of relevant participant characteristics will be used to assign the
participant to a medication. Dosing will be determined by each participant's psychiatrist.
Participants will be followed for up to 5 years to assess the side effects of the study
medications, with study visits at baseline, Week 6, and every 3 months thereafter.
|
| Criteria: |
|
Inclusion Criteria:
- DSM-IV diagnosis of a disease or disorder that requires treatment with an atypical
antipsychotic medication
Exclusion Criteria:
- N/A
|
| NCT ID: |
|
NCT00245206 |
| Primary Contact: |
|
Principal Investigator
Dilip V. Jeste, MD
University of California, San Diego
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
San Diego, California 92037
United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 24, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|